 After PD, selection of second-line therapy, when clinically indicated, is at the discretion of the investigator and can include second-line PCI-32765 for patients randomized to chlorambucil in the parent study who also meet the criteria for second-line PCI-32765 therapy, second-line chlorambucil for patients randomized to PCI-32765 in the parent study, or other therapies. 